Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF V600E mutation.
Susana Garcia-SilvaAlberto Benito-MartínSara Sánchez-RedondoAlberto Hernández-BarrancoPilar Ximénez-EmbúnLaura NoguésMarina S MazariegosKay BrinkmannAna Amor LópezLisa MeyerCarlos RodríguezCarmen García-MartínJasminka BoskovicRocío LetónCristina MonteroMercedes RobledoLaura SantambrogioMary Sue BradyAnna Szumera-CiećkiewiczIwona KalinowskaJohan SkogMikkel NoerholmJavier MuñozPablo L Ortiz-RomeroYolanda RuanoJosé L Rodríguez-PeraltoPiotr RutkowskiHector PeinadoPublished in: The Journal of experimental medicine (2019)
Liquid biopsies from cancer patients have the potential to improve diagnosis and prognosis. The assessment of surrogate markers of tumor progression in circulating extracellular vesicles could be a powerful non-invasive approach in this setting. We have characterized extracellular vesicles purified from the lymphatic drainage also known as exudative seroma (ES) of stage III melanoma patients obtained after lymphadenectomy. Proteomic analysis showed that seroma-derived exosomes are enriched in proteins resembling melanoma progression. In addition, we found that the BRAFV600E mutation can be detected in ES-derived extracellular vesicles and its detection correlated with patients at risk of relapse.
Keyphrases
- lymph node
- end stage renal disease
- ultrasound guided
- chronic kidney disease
- newly diagnosed
- skin cancer
- ejection fraction
- mesenchymal stem cells
- early stage
- stem cells
- prognostic factors
- poor prognosis
- robot assisted
- risk assessment
- lymph node metastasis
- patient reported
- patient reported outcomes
- human health
- climate change
- sentinel lymph node
- real time pcr